期刊
EUROPEAN JOURNAL OF CANCER
卷 182, 期 -, 页码 144-154出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2022.12.032
关键词
Non-seminomatous germ cell tumour; Retroperitoneal lymph node dissection; International Germ Cell Cancer Cooperative Group; Teratoma
类别
This study analyzed the proportion of residual teratoma and survival among patients with intermediate/poor prognosis after first-line chemotherapy. The results showed that most patients relapsed only in the retroperitoneum after undergoing surgery, and there was no significant difference in overall survival between the two groups.
Introduction: Current guidelines recommend surveillance in metastatic non-semi-nomatous germ cell tumour patients treated with first-line-chemotherapy and a complete clin-ical response (normalisation of serum tumour markers and residual masses <1 cm). However, this recommendation is based on a series including patients with good prognosis according to International Germ Cell Cancer Cooperative Group prognostic group (IGCCCG-PG). The aim of this study was to analyse the proportion of residual teratoma and survival among pa-tients with intermediate/poor IGCCCG-PG and a complete clinical response after first-line -chemotherapy. Material & methods: This is a retrospective study of men with intermediate/poor IGCCCG-PG, who had a complete clinical response after first-line chemotherapy. Patients were either followed by surveillance or treated with post-chemotherapy retroperitoneal lymph node dissection (pcRPLND). Results: Between 2009 and 2018, 143 men with intermediate (n = 83) or poor (n = 60) IGCCCG-PG were treated at 11 international centres. Among 33 patients treated with pcRPLND, the specimen showed teratoma and viable cancer in 16 (48%) and 4 (12%). During a median a 7-year follow-up, 20/110 (18%) patients managed with surveillance relapsed, of whom seven (6%) had a retroperitoneal-only relapse versus 2/33 patients managed with pcRPLND relapsed. No difference was observed regarding overall survival (OS) among men treated with pcRPLND or surveillance (5-year OS, 93% and 89%, p-value = 0.35). The median time-to-recurrence among men on surveillance was 1.3 years (range: 0.3-9.1), and the most common sites of relapses included retroperitoneum (11%), chest (5%), and bones (4%). Conclusions: While most men with intermediate/poor IGCCCG-PG harbour teratoma/cancer in the retroperitoneum despite a complete response to first-line-chemotherapy, only 6% managed with surveillance relapsed in the retroperitoneum. There was no significant difference in OS between the two groups. 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据